(4R,6R)-6-[2-[1,5-bis(4-fluorophenyl)-3-propan-2-ylpyrazol-4-yl]ethyl]-4-hydroxyoxan-2-one | 116645-12-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (4R,6R)-6-[2-[1,5-bis(4-fluorophenyl)-3-propan-2-ylpyrazol-4-yl]ethyl]-4-hydroxyoxan-2-one
• CAS: 116645-12-6；124288-15-9
• 化学式: C₂₅H₂₆F₂N₂O₃
• 分子量: 440.49
• InChiKey: CJOOCCJIHMSWOT-NHCUHLMSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.94
• 重原子数：
  32.0
• 可旋转键数：
  6.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  64.35
• 氢给体数：
  1.0
• 氢受体数：
  5.0

反应信息

• 作为产物：
  描述：

  1-(4-氟苯基)-4-甲基戊-1,3-二酮 在 sodium hydride 、 sodium iodide 作用下， 反应 36.0h， 生成 (4R,6R)-6-[2-[1,5-bis(4-fluorophenyl)-3-propan-2-ylpyrazol-4-yl]ethyl]-4-hydroxyoxan-2-one
  参考文献：
  名称：

  Inhibitors of cholesterol biosynthesis. 2. 1,3,5-Trisubstituted [2-(tetrahydro-4-hydroxy-2-oxopyran-6-yl)ethyl]pyrazoles

  摘要：

  A series of 1,3,5-trisubstituted pyrazole mevalonolactones were prepared and evaluated for their ability to inhibit the enzyme HMG-CoA reductase in vitro. Since previous studies suggested that the 5-(4-fluorophenyl) and 3-(1-methylethyl) substituents afforded optimum potency, attention was focused on variations in position 1 of the pyrazole ring. Biological evaluation of analogues bearing a variety of 1-substituents suggested that, although most substituents were tolerated, none afforded an advantage over phenyl, which exhibited potency comparable to that of compactin in vitro.

  DOI：

  10.1021/jm00163a006